Abstract
PurposeMenin, encoded by the MEN1 gene, was recently reported to be involved in breast cancers, though the underlying mechanisms remain elusive. In the current study, we sought to further determine its role in mammary cells.MethodsMenin expression in mammary lesions from mammary-specific Men1 mutant mice was detected using immunofluorescence staining. RT-qPCR and western blot were performed to determine the role of menin in ERα expression in human breast cancer cell lines. ChIP-qPCR and reporter gene assays were carried out to dissect the action of menin on the proximal ESR1 promoter. Menin expression in female patients with breast cancer was analyzed and its correlation with breast cancer subtypes was investigated.ResultsImmunofluorescence staining revealed that early mammary neoplasia in Men1 mutant mice displayed weak ERα expression. Furthermore, MEN1 silencing led to both reduced ESR1 mRNA and ERα protein expression in MCF7 and T47D cells. To further dissect the regulation of ESR1 transcription by menin, we examined whether and in which way menin could regulate the proximal ESR1 promoter, which has not been fully explored. Using ChIP analysis and reporter gene assays covering − 2500 bp to + 2000 bp of the TSS position, we showed that the activity of the proximal ESR1 promoter was markedly reduced upon menin downregulation independently of H3K4me3 status. Importantly, by analyzing the expression of menin in 354 human breast cancers, we found that a lower expression was associated with ER-negative breast cancer (P = 0.041). Moreover, among the 294 ER-positive breast cancer samples, reduced menin expression was not only associated with larger tumors (P = 0.01) and higher SBR grades (P = 0.005) but also with the luminal B-like breast cancer subtype (P = 0.006). Consistent with our clinical data, we demonstrated that GATA3 and FOXA1, co-factors in ESR1 regulation, interact physically with menin in MCF7 cells, and MEN1 knockdown led to altered protein expression of GATA3, the latter being a known marker of the luminal A subtype, in MCF7 cells.ConclusionTaken together, our data provide clues to the important role of menin in ERα regulation and the formation of breast cancer subtypes.
Highlights
Breast cancers are among the most common malignancies worldwide and remain the leading cause of cancer-related mortality in women [1]
We previously reported the occurrence at a high incidence of mammary intraepithelial neoplasia (MIN) lesions, displaying weak ERα expression, in Men1 mammary conditional mutant mice [19]
ERα was expressed in approximately 52.5% of luminal cells expressing menin in the former group (Fig. 1a, upper panel), whereas immunofluorescence revealed that ERα expression was nearly 3.2-fold lower in Men1-deficient cells in Men1F/F-WapCre+ mice, compared to Men1F/F-WapCre− mice
Summary
Breast cancers are among the most common malignancies worldwide and remain the leading cause of cancer-related mortality in women [1]. The luminal A subtype encompasses approximately 44% of breast cancers This subtype is estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive and human epidermal growth factor receptor 2 (HER2)-negative, which displays a reduced expression of proliferation-related genes [3] and is sensitive to endocrine therapy with an overall favorable prognosis. The luminal B subtype represents around 20% of breast cancers and displays lower expression of ERα-related genes, a variable expression of (HER2), and a higher expression of proliferation-related genes [4]. This subtype harbors more genomic instability and has a poorer prognosis than the luminal A subtype [5]. The triple-negative breast cancer (TNBC) subtype is negative for all three receptors [6] and is the most aggressive with the worst prognosis
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have